Alector (ALEC) Q2 2024 earnings summary

Executive summary

• Advanced clinical pipeline with key data readouts expected for AL002 (TREM2 agonist) in Q4 2024 and latozinemab (progranulin-elevating antibody) in late 2025/early 2026; pivotal INFRONT-3 Phase 3 trial for latozinemab is fully enrolled.

• FDA granted breakthrough therapy designation to latozinemab for FTD with GRN mutations, providing regulatory clarity and increased agency interaction.

• Launched Alector Brain Carrier (ABC) platform to enhance CNS drug delivery, expanding preclinical and clinical capabilities.

• Collaborations with GSK and AbbVie continue to provide significant funding and cost-sharing for clinical programs.

• Reported a net loss of $38.7M for Q2 2024 and $74.8M for the first half of 2024, with an accumulated deficit of $784.8M as of June 30, 2024.

Financial highlights

• Ended Q2 2024 with $503.3 million in cash, cash equivalents, and marketable securities, supporting operations through 2026.

• Q2 2024 collaboration revenue was $15.1 million, down from $56.2 million in Q2 2023, mainly due to lower AL101 and AL002 program revenue.

• R&D expenses were $46.3 million in Q2 2024, flat year-over-year; G&A expenses rose to $14.4 million.

• Net loss per share was $(0.40) for Q2 2024, compared to $0.02 earnings per share in Q2 2023.

• Deferred revenue was $263.5M as of June 30, 2024, related to GSK and AbbVie collaborations.

Outlook and guidance

• Cash runway extends through 2026, a year past the pivotal INFRONT-3 phase III readout for latozinemab.

• 2024 collaboration revenue guidance: $60–70 million; R&D expense guidance: $210–220 million; G&A guidance: $60–70 million.

• AbbVie opt-in decision for AL002 expected by Q2 2025, potentially triggering a $250 million payment.

• The company anticipates continued net losses and may seek additional capital through equity, debt, or collaborations.